TEX CORE
Innovative Tumor Targeting Technology
InnovoTEX is developing its TEX CORE platform for compounds that are tumor-localizing, well-tolerated, and use a multi-modal design for multiple solid tumor indications.
OxaliTEX
OxaliTEX-Pt(IV) is the first product candidate being developed from the TEX CORE platform. Initial indication is platinum-resistant ovarian cancer.
AuraTEX
AuraTEX is a novel gold-based therapy that can both eradicate cancer and stimulate an anti-cancer immune response.
NEWS
Anil Sood, MD joins Scientific and Medical Advisory Board
Dr. Sood is the Director of the Cancer Moon Shot Program and Vice Chair of Gynecologic Oncology at MD Anderson Cancer Center.
InnovoTEX announced WINNER of the Global Health Innovation Challenge
Sponsored by the Center for Advancing Innovation
Press releases and publications.
Immunogenic cell death-inducing metal complexes: From the benchtop to the clinic
InnovoTEX selected to participate in the Texas Medical Center's Accelerator for Cancer Therapeutics program